Daiwa Securities Group’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-357
| Closed | -$5K | – | 1358 |
|
|
2025
Q4 | $5K | Hold |
357
| – | – | ﹤0.01% | 1239 |
|
|
2025
Q3 | $5K | Hold |
357
| – | – | ﹤0.01% | 1207 |
|
|
2025
Q2 | $6K | Hold |
357
| – | – | ﹤0.01% | 1149 |
|
|
2025
Q1 | $6K | Hold |
357
| – | – | ﹤0.01% | 1124 |
|
|
2024
Q4 | $11K | Sell |
357
-65
| -15% | -$1.38K | ﹤0.01% | 1113 |
|
|
2024
Q3 | $7K | Sell |
422
-4,620
| -92% | -$83.8K | ﹤0.01% | 1152 |
|
|
2024
Q2 | $87K | Sell |
5,042
-80
| -2% | -$1.41K | ﹤0.01% | 1036 |
|
|
2024
Q1 | $80K | Buy |
5,122
+4,700
| +1,114% | +$69.1K | ﹤0.01% | 1067 |
|
|
2023
Q4 | $6K | Hold |
422
| – | – | ﹤0.01% | 1196 |
|
|
2023
Q3 | $7K | Sell |
422
-9,766
| -96% | -$282K | ﹤0.01% | 1139 |
|
|
2023
Q2 | $423K | Sell |
10,188
-1,231
| -11% | -$76.4K | ﹤0.01% | 854 |
|
|
2023
Q1 | $686K | Buy |
11,419
+191
| +2% | +$15.3K | ﹤0.01% | 748 |
|
|
2022
Q4 | $824K | Sell |
11,228
-415
| -4% | -$31.2K | 0.01% | 696 |
|
|
2022
Q3 | $884K | Sell |
11,643
-278
| -2% | -$21.7K | 0.01% | 675 |
|
|
2022
Q2 | $829K | Buy |
11,921
+1,951
| +20% | +$147K | 0.01% | 705 |
|
|
2022
Q1 | $826K | Buy |
9,970
+1,981
| +25% | +$146K | 0.01% | 749 |
|
|
2021
Q4 | $600K | Buy |
7,989
+487
| +6% | +$48.9K | ﹤0.01% | 825 |
|
|
2021
Q3 | $871K | Sell |
7,502
-1,886
| -20% | -$285K | 0.01% | 714 |
|
|
2021
Q2 | $2.08M | Sell |
9,388
-340
| -3% | -$66.1K | 0.01% | 440 |
|
|
2021
Q1 | $1.29M | Buy |
9,728
+3,916
| +67% | +$619K | 0.01% | 544 |
|
|
2020
Q4 | $1M | Buy |
5,812
+827
| +17% | +$113K | 0.01% | 570 |
|
|
2020
Q3 | $554K | Buy |
4,985
+4,426
| +792% | +$354K | 0.01% | 667 |
|
|
2020
Q2 | $32K | Hold |
559
| – | – | ﹤0.01% | 965 |
|
|
2020
Q1 | $38K | Hold |
559
| – | – | ﹤0.01% | 969 |
|
|
2019
Q4 | $41K | Sell |
559
-66
| -11% | -$5.33K | ﹤0.01% | 973 |
|
|
2019
Q3 | $47K | Buy |
625
+21
| +3% | +$1.68K | ﹤0.01% | 961 |
|
|
2019
Q2 | $38K | Hold |
604
| – | – | ﹤0.01% | 979 |
|
|
2019
Q1 | $29K | Buy |
604
+110
| +22% | +$5.29K | ﹤0.01% | 976 |
|
|
2018
Q4 | $17K | Hold |
494
| – | – | ﹤0.01% | 974 |
|
|
2018
Q3 | $26K | Hold |
494
| – | – | ﹤0.01% | 989 |
|
|
2018
Q2 | $15K | Hold |
494
| – | – | ﹤0.01% | 1024 |
|
|
2018
Q1 | $11K | Buy |
+494
| New | +$10.6K | ﹤0.01% | 1026 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
Daiwa Securities Group's NVCR Position: Q1 2026 in Review
Daiwa Securities Group sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 357 shares — an estimated $5K sold.
Daiwa Securities Group first reported a position in NVCR in Q1 2018 and held it in 32 quarters. The position peaked at $2.08M in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Daiwa Securities Group reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 357 NovoCure shares in Q1 2026, an estimated $5K.
- Daiwa Securities Group first reported a position in NovoCure in Q1 2018 and held it in 32 quarters.
- Daiwa Securities Group's NovoCure position peaked at $2.08M in Q2 2021.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.